Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for anti-Hu paraneoplastic neurological syndromes
NL-OMON28171Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of natalizumab in paraneoplastic neurological syndrome (PNS), sponsored by Erasmus MC. Primary endpoint: Functional improvement on modified Rankin Scale. Started Apr 2016; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
paraneoplastic neurological syndrome (PNS)
Beyond the preview
Go deeper on NL-OMON28171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28171.